Clinical Study Results
Research Sponsor: AstraZeneca
Drug Studied: Anifrolumab
Study Title: A study to find out if anifrolumab reduces lupus symptoms in participants with lupus

Thank you!

Thank you to the participants who took part in the clinical study for the study drug anifrolumab, also called MEDI-546. All the participants helped researchers learn more about anifrolumab to help people with systemic lupus erythematosus, also called lupus or SLE.

AstraZeneca sponsored this study and thinks it is important to share the results of the study with the participants and the public. An independent non-profit organization called CISCRP helped prepare this summary of the study results. We hope it helps you understand and feel proud of your important role in medical research.

If you participated in the study and have questions about the results, please speak with the doctor or staff at your study site.

What is happening with the study now?

Participants were in the study for up to 64 weeks, but the entire study took more than 3 years to finish. The study started in June 2015 and ended in July 2018.

The study included a total of 457 participants from Argentina, Australia, Brazil, Chile, Colombia, Germany, Hungary, Israel, Italy, New Zealand, Peru, Poland, Romania, South Korea, Taiwan, Ukraine, the United Kingdom, and the United States.

The sponsor reviewed the data collected when the study ended and created a report of the results. This is a summary of that report.